Active Injection Drug-Abuse Offsets Healthcare Engagement in HIV-Infected Patients

AIDS and Behavior

Volumn 19, Issue 1, 2015, Pages 81-84

  Liappis, Angelike P ^a,b   Laake, Ann M ^a,b   Delman, Mark ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Addiction; AIDS; Bacteremia; Drug abuse; HIV; Mortality

Indexed keywords

ADULT; DRUG USE; FEMALE; HEALTH CARE DELIVERY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MIXED INFECTION; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; UNITED STATES; URBAN POPULATION; VETERAN;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COINFECTION; DISTRICT OF COLUMBIA; DRUG USERS; FEMALE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; SUBSTANCE ABUSE, INTRAVENOUS; URBAN POPULATION; VETERANS;

EID: 84897359632     PISSN: 10907165     EISSN: 15733254     Source Type: Journal    
DOI: 10.1007/s10461-014-0757-4     Document Type: Article

References (11)

1. Murray M, Hogg RS, Lima VD, et al. The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. HIV Med. 2012;13(2):89–97.
2. Larsen MV, Omland LH, Gerstoft J, et al. Impact of injecting drug use on mortality in Danish HIV-infected patients: a nation-wide population-based cohort study. Addiction. 2010;105(3):529–35.
3. Salter ML, Lau B, Go VF, et al. HIV infection, immune suppression, and uncontrolled viremia are associated with increased multimorbidity among aging injection drug users. Clin Infect Dis. 2011;53(12):1256–64.
4. Martin EG, Wang KH. Integrating substance abuse treatment into HIV care: missed opportunities in the AIDS Drug Assistance Program. J Acquir Immune Defic Syndr. 2013;62(4):421–9.
5. Bruce RD, Kresina TF, McCance-Katz EF. Medication-assisted treatment and HIV/AIDS: aspects in treating HIV-infected drug users. AIDS. 2010;24(3):331–40.
6. Altice FL, Kamarulzaman A, et al. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376(9738):367–87.
7. Floris-Moore M, Lo Y, Klein RS, et al. Gender and hospitalization patterns among HIV-infected drug users before and after the availability of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2003;34(3):331–7.
8. Palepu A, Tyndall MW, Leon H, et al. Hospital utilization and costs in a cohort of injection drug users. CMAJ. 2001;165(4):415–20.
9. Kohli R, Lo Y, Howard AA, et al. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;41(6):864–72.
10. Yehia BR, Fleishman JA, Wilson L, et al. HIV Research Network. Incidence of and risk factors for bacteraemia in HIV-infected adults in the era of highly active antiretroviral therapy. HIV Med. 2011;12(9):535–43.
11. Burkey MD, Wilson LE, Moore RD, et al. The incidence of and risk factors for MRSA bacteraemia in an HIV-infected cohort in the HAART era. HIV Med. 2008;9(10):858–62.